Stereotaxis’ System Deployed at the University of Chicago Medicine
Shares of Stereotaxis Inc (NASDAQ:STXS) continue to gain value after the company said on Wednesday that the University of Chicago Medicine will implement its Niobe ES remote magnetic navigation system as part of a plan to create a cutting-edge arrhythmia technology suite. A press release by the St. Louis, Missouri-based company said that the Niobe system is a revolutionary invention in the field of cardiac ablation which helps treat the difficult-to-reach arrhythmias with high precision. Last week, Stereotaxis announced that the Texas Children’s Hospital in Houston also installed its Niobe ES system. Shares are up by 7% today and have soared by 33% over the past six trading sessions. Only four funds tracked by us held long positions in Stereotaxis Inc (NASDAQ:STXS) at the end of the first quarter.
Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) is taking it on the chin today, nosediving by 13% so far today. Shares of the biotechnology company, which is set to announce the results of its Phase 2 Study of NurOwn in Patients with ALS on July 18, had skyrocketed by 33% on Thursday. At the end of March, three hedge funds in our system held shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI).
Great Basin Scientific Sinks on Preliminary Results
Great Basin Scientific Inc (NASDAQ:GBSN) has lost 17.86% of its value today following the release of its preliminary results for the second quarter of 2016. Revenue for the quarter came in at $728,957, a 38.7% increase compared to the same quarter of last year. The company added 38 new customers during the quarter, lifting its customer base to 260. It’s unclear why the market has reacted so negatively to the company’s press release, which appears to be relatively positive. No funds that we track were long Great Basin Scientific Inc (NASDAQ:GBSN) as of March 31, after John Overdeck and David Siegel’s Two Sigma Advisors sold out of their small position in the stock during the first quarter.